DIFFERENCE IN BLOOD FUNCTION TOXICITY BETWEEN STADIUM IIB-IIIB SQUAMOUS CELL CERVICAL CANCER PATIENTS WITH PACLITAXEL CISPLATIN AND PACLITAXEL CARBOPLATIN CHEMOTHERAPY AT SANGLAH HOSPITAL, DENPASAR.

Indrayathi Pa; Noviyani R; Niruri R; Budiana Ing; Tunas K

doi:10.22159/ajpcr.2018.v11i1.22125

Authors

Indrayathi Pa Department of Public Health, Faculty of Medicine, Udayana University, Bali, Indonesia.
Noviyani R Department of Pharmacy, Faculty of Mathematics and Sciences, Udayana University, Bali, Indonesia.
Niruri R Department of Pharmacy, Faculty of Mathematics and Sciences, Udayana University, Bali, Indonesia.
Budiana Ing Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University, Bali, Indonesia.
Tunas K Department of Public Health, Faculty of Health, Science and Technology, Dhyana Pura University, Bali,Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i1.22125

Keywords:

Chemotherapy, Cervical cancer, Paclitaxel cisplatin, Paclitaxel carboplatin, Hemoglobin, Thrombocyte, Leukocyte

Abstract

Â Objective: Paclitaxel cisplatin and paclitaxel carboplatin were chemotherapy regimens used for cervical cancer treatments at Sanglah Hospital, Denpasar. They came with hematologic toxicity side effects. This could be monitored from hemoglobin, thrombocyte, and leukocyte parameter. Data that compared the toxicity of these two regimens were still limited at Sanglah Hospital, Denpasar. Therefore, it was necessary to conduct a research about the difference in blood function toxicity between patients who underwent paclitaxel cisplatin chemotherapy and those who underwent paclitaxel carboplatin chemotherapy based on those three parameters.

Methods: This was a prospective observational research with consecutive sampling, inclusion, and exclusion criteria. It was carried out from January to August 2016 at Sanglah Hospital, Denpasar. Patients were categorized into two groups based on their chemotherapy regimens. Next, blood samples from both groups were tested for its hemoglobin, thrombocyte, and leukocyte level before and after chemotherapy. The data underwent normality test using either Shapiroâ€“Wilk or Mannâ€“Whitney test with SPSS.

Results: There were 17 patients who fulfilled the inclusion criteria. The result showed a decrease in hemoglobin, thrombocyte, as well as leukocyte values in patients who underwent paclitaxel cisplatin and paclitaxel carboplatin chemotherapy.

Conclusion: The decrease of both hemoglobin and leukocyte level was not meaningful in both groups (p>0.05). Meanwhile, the decrease of thrombocyte level was meaningful in both groups (*p<0.05) in which patients who belong to paclitaxel carboplatin chemotherapy group showed a higher decrease of thrombocyte values.

Downloads

Download data is not yet available.

Author Biographies

Indrayathi Pa, Department of Public Health, Faculty of Medicine, Udayana University, Bali, Indonesia.

Department of Public Health, Faculty of Medicine, 1

Noviyani R, Department of Pharmacy, Faculty of Mathematics and Sciences, Udayana University, Bali, Indonesia.

Department of Pharmacy, Faculty of Mathematics and Natural Science 2

Niruri R, Department of Pharmacy, Faculty of Mathematics and Sciences, Udayana University, Bali, Indonesia.

Department of Pharmacy, Faculty of Mathematics and Natural Science, 2

Budiana Ing, Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University, Bali, Indonesia.

Department of Obstetrics and Gynecology, Faculty of Medicine, 3

Tunas K, Department of Public Health, Faculty of Health, Science and Technology, Dhyana Pura University, Bali,Indonesia.

Department of Public Health, Faculty of Health, Science and Technology, 4

References

Kemenkes RI. (Kementrian Kesehatan Republik Indonesia). Pusat Data dan Informasi Kementrian Kesehatan RI. Jakarta: Kementerian Kesehatan Republik Indonesia; 2015a.

Kemenkes RI. Panduan Pelayanan Klinis Kanker Serviks. Jakarta: Kementerian Kesehatan Republik Indonesia; 2015b.

Skeel RT, Khleif SN. Handbook of Cancer Chemotherapy. 8th ed. Philladelphia, PA: Lippincot William and Wilkins, A Wolters Kluwer Business; 2011. p. 118-25.

Komite Medik RSUP Sanglah. Protokol Kemoterapi Onkologi Ginekologi. Denpasar: Rumah Sakit Umum Pusat Sanglah; 2011.

Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 2004;22:3113-9.

Hoskins WJ, Perez CA, Young RC. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005.

Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The open-label randomized Phase III Trial JCOG0505. J Clin Oncol 2015;33:2129-35.

Andrijono AF, Saiffudin AB. Buku Acuan Nasional Onkologi Ginekologi. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2006.

Anderson PO, Knoben JE, Troutman WG. Handbook of Clinical Drug Data. 10th ed. USA: McGraw-Hill Companies, Inc; 2002.

Smith IE, Oâ€™Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-43.

Herfindal ET, Gourley DR. Textbook of Therapeutics Drugs and Disease Management. USA: Lippincott Williams & Wilkins; 2000.

WHO (World Health Organization). Comprehensive Cervical Cancer Control A Guide to Essential Practice. Switzerland: World Health Organization; 2014.

Lasut E, Rarung M, Suparman E. Karakteristik penderita kanker serviks di BLU RSUP Prof. Dr. R. D. Kandou. J e-Clin 2015;3:83-6. Available from:https://www.ejournal.unsrat.ac.id/index.php/eclinic/article/view/6519.

Dandal A, Abajy MY, Alkhalaf M, Ibrahim A. Prevalence of human papilloma virus Types 16 And 18 among women with cervical cancer in aleppo, Syria. Int J Pharm Sci 2017;9:90-3. Available from: https://www.innovareacademics.in/journals/index.php/ijpps/article/view/18773/12125.

Pandey D, Shetty J, Sambhaji C, Saxena PU, Mishra D, Chawla A. Cervical Cancer as a silent killer: A rare case report with review of literature. J Cancer Res Ther 2015;11:653.

Antony A, Joel JJ, Shetty J, Umar NF. Identification and analysis of adverse drug reactions associated with cancer chemotherapy in hospitalized patients. Int J Pharm Sci 2016;8:448-51. Available from: http://www.innovareacademics.in/journals/index.php/ijpps/article/view/11601/6208.

Park DC, Kim JH, Lew YO, Kim DH, Namkoong SE. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol 2004;92:59-63.

Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:1356-65.

Umayahara K, Takekuma M, Hirashima Y, Noda SE, Ohno T, Miyagi E, et al. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial. Gynecol Oncol 2016;140:253-8.

Rodgers GM. Managing patients with chemotherapy-induce anemia. Adv Stud Med 2008;8:346-51. Available from: http://www.qu.edu.qa//2B_Chemotherapy-Induced_Anemia.pdf.

El-Deen DS, Al-Shahat M, El-Metwaly AE. Weekly paclitaxel and carboplatin for patients with advanced ovarian cancer. Med J Cairo Univ 2012;8025-31. Available from http//www.erepository.cu.edu.eg/index.php/MJCU/article/view/977/954.

Handayani W, Haribowo AS. Buku Ajar Asuhan Keperawatan pada Klien dengan Gangguan Sistem Hematologi. Jakarta: Salemba Medika; 2008.

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. United States of America: The McGraw-Hill Companies, Inc; 2002.

Kee JL, Hayes ER. Farmakologi: Pendekatan Proses Keperawatan. Jakarta: Penerbit Buku Kedokteran EGC; 1994.

Dollery C. Therapeutic Drugs. 2nd ed. United Kingdom: Churchill Livingstone; 1999.

Joseph S, Pradeep S, Jayakumar KL. A prospective comparative study of the toxicity profile in patients receiving cisplatin-paclitaxel vs carboplatin-paclitaxel in advanced ovarian cancer. Int J Med Pharm Sci 2015;6:1-5. Available from: http://www.scopemed.org/?mno=205116.

Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 2002;13:1539-49.

du Bois A, LÃ¼ck HJ, Meier W, Adams HP, MÃ¶bus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9.

Gibson J. Fisiologi dan Anatomi Modern untuk Perawat. Jakarta: ECG; 2003.

Sweetman SC. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.

Panichevaluk A. Phase II study of paclitaxel plus carboplatin in recurrent and/or metastatic cervical carcinoma. Thai J Obstet Gynaecol 2003;15:33-7. Available from: http://www.tci-thaijo.org/index.php/tjog/article/view/82779.

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.

Cassidy J, Bissett D, Obe RA. Oxford Handbook of Oncology. New York: Oxford University Press; 2002.